Page 106 - DUOKOPT BIBLIOBOOK

DUOKOPT - bibliography book - CONFIDENTIAL - document for exclusive use by personnel of Laboratoires Théa – DO NOT DISTRIBUTE
®

KEY MESSAGES

X The results show significantly lower rates of progression of glaucomatous damage with
dorzolamide and timolol compared with timolol alone.

STRENGTHS

X A 4 year prospective study.
X In 4-year, open-label study in patients with primary open-angle glaucoma, dorzolamide
2% BID added to timolol 0.5% BID was associated with a significant reduction in IOP and
significant increases in retrobulbar hemodynamic parameters in both the ophthalmic
and short posterior ciliary arteries.

X Dorzolamide added to timolol may be effective in preventing progression of glauco-
matous visual field damageTFC.
X Both visual field examinations and CDI (Colour Dopper Imaging) were conducted in
masked fashion may have reduced the potential for bias. The both eyes were included
in the analysis.

WEAKNESSES

X The study lack of data on compliance and tolerability.
X The study compare eyes with different degrees of visual field damage, differences in
progression between study and control eyes may be explained by a regression to the
mean effect.

MARKETING CLAIM

X Dorzolamide-Timolol combination shows a reduction IOP even in the long term.
X Fixed combination brings added value in the progression rate of glaucomatous damage
Vs timolol alone.

106